View More View Less
  • 1 Bács-Kiskun Megyei Kórház, Urológiai Osztály, Kecskemét
  • 2 Országos Orvosi Rehabilitációs Intézet, Urodinamikai Labor, Budapest
  • 3 Szegedi Tudományegyetem, Általános Orvostudományi Kar, Sebészeti Műtéttani Intézet, Szeged, Pulz u. 1., 6724

Összefoglaló. Az alsó húgyutak fő funkciója a vizelet tárolása és ürítése, amely működések zavara az úgynevezett alsó húgyúti tünetegyüttes kialakulásához vezet, ami a kiváltó októl függően vizeletürítési zavarral és vizeletretencióval is járhat. Kezeletlen esetekben a felső húgyutak károsodása következik be a magas hólyagnyomás által kiváltott vesicoureteralis reflux következtében, amely ureter- és veseüregrendszeri tágulat kialakulására, illetve fertőzésekre és kőképződésre hajlamosít. A vizelettárolási/vizeletürítési zavarokat három fő csoportba sorolhatjuk, úgymint stressz- (terheléses) inkontinencia , hiperaktív hólyag (nedves/száraz) és neurogén hólyag. A jelen összefoglaló közlemény tárgyát képező neurogén hólyag egy gyűjtőfogalom, mely magában foglal minden, releváns neurológiai kórkép talaján kialakult vizelettárolási és vizeletürítési zavart. Mivel a húgyhólyag mellett a záróizomzat és a hátsó húgycső is érintett, ezt a kórképet napjainkban „neurogén alsó húgyúti diszfunkció” elnevezéssel is szokás illetni. A kórállapotot a neurológiai diszfunkciók széles spektruma okozhatja, kezdve a helyi funkcionális zavartól a helyi idegi sérülésen át a felső és alsó motoneuron-sérülésig vagy a centrális degeneratív folyamatokig. Az eltérő etiológia ellenére a klinikai tünetek rendszerint két alapvető klinikai típusban manifesztálódhatnak: túlműködő (fokozott detrusorkontraktilitást okozó automata) hólyag vagy alulműködő hólyag formájában. Tekintettel a neurogén alsó húgyúti diszfunkció következtében létrejövő felső húgyúti komplikációkra, a közlemény egyik célja a betegség diagnózisát segítő algoritmus bemutatása a legújabb nemzetközi szakirodalmi ismeretek alapján. A neurogén hólyag kezelése jobbára nem terjedhet ki a kiváltó ok kezelésére, ezért a jelen összefoglaló másik célja azon gyógyszeres és invazív terápiás beavatkozások összefoglalása, melyek a felső húgyutak védelmét szolgálják az alacsony hólyagnyomás fenntartása révén. Orv Hetil. 2021; 162(4): 135–143.

Summary. Storage and urination are the main functions of the lower urinary tract and its lesions lead to the so-called lower urinary tract syndrome causing either urinary incontinence or retention. In untreated cases, the upper urinary tract becomes injured via a vesicoureteral reflux resulting from increased bladder pressure and resultant dilations of the ureter and the renal pelvis which predispose to infection and stone formation. Lower urinary tract storage/urination disorders can be classified as stress incontinence, hyperactive bladder (wet/dry) and neurogenic bladder. Neurogenic bladder which is the subject of this review, is a collective term that encompasses all urinary storage and emptying disorders which develop on the basis of neurological diseases. Being not only the bladder, but also the sphincter and posterior urethra (generally termed as the “bladder outlet”) affected, nowadays this condition is referred to as “neurogenic lower urinary tract dysfunction”. A wide range of neurological dysfunctions could contribute to the development of this condition, ranging from local dysfunction (autonomic dysreflexia) or local nerve injury to upper/lower motoneuron injury or central degenerative processes. Regardless of the diverse etiology, the clinical symptoms eventually manifest in two major forms, i.e., overacting (automatic bladder with increased detrusor contractility) and underactive bladder. Considering the severity of complication occurring in the upper urinary tract in response to the pathophysiological changes in the lower urinary tract, one of the aims of this paper was to present an algorithm aiming to build up a state of the art diagnosis of the disease based on current international literature data. Since treatment of the neurogenic bladder usually can not target elimination of the underlying cause, the other goal of the present paper is to summarize the pharmacological treatment regimen and invasive therapeutic interventions that protect the upper urinary tract by maintaining low pressure values in the bladder. Orv Hetil. 2021; 162(4): 135–143.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Torre M, Guida E, Bisio G, et al. Risk factors for renal function impairment in a series of 502 patients born with spinal dysraphisms. J Pediatr Urol. 2011; 7: 39–43.

  • 2

    Cameron AP, Wallner LP, Tate DG, et al. Bladder management after spinal cord injury in the United States 1972 to 2005. J Urol. 2010; 184: 213–217.

  • 3

    Nortvedt MW, Riise T, Frugård J, et al. Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. Mult Scler. 2007; 13: 106–112.

  • 4

    Nicholas RS, Friede T, Hollis S, et al. Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev. 2009; (1): CD004193.

  • 5

    Urology Care Foundation. What is neurogenic bladder? Available from: https://www.urologyhealth.org/urologic-conditions/neurogenic-bladder [accessed: July 29, 2020].

  • 6

    Amarenco G, Sheikh Ismaël S, Chesnel C, et al. Diagnosis and clinical evaluation of neurogenic bladder. Eur J Phys Rehabil Med. 2017; 53: 975–980.

  • 7

    Allio BA, Peterson AC. Urodynamic and physiologic patterns associated with the common causes of neurogenic bladder in adults. Transl Androl Urol. 2016; 5: 31–38.

  • 8

    Cameron AP. Medical management of neurogenic bladder with oral therapy. Transl Androl Urol. 2016; 5: 51–62.

  • 9

    Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol. 2015; 14: 720–732.

  • 10

    Blok B, Castro-Diaz D, Del Popolo G, et al. European Association of Urology (EAU) Guidelines. Available from: https://uroweb.org/guideline/neuro-urology/ [accessed: July 29, 2020].

  • 11

    Pannek J, Kullik B. Does optimizing bladder management equal optimizing quality of life? Correlation between health-related quality of life and urodynamic parameters in patients with spinal cord lesions. Urology 2009; 74: 263–266.

  • 12

    Chuang FC, Hsiao SM, Kuo HC. The Overactive Bladder Symptom Score, International Prostate Symptom Score–Storage Subscore, and Urgency Severity Score in patients with overactive bladder and hypersensitive bladder: which scoring system is best? Int Neurourol J. 2018; 22: 99–106.

  • 13

    Podnar S, Vodusek DB. Protocol for clinical neurophysiologic examination of the pelvic floor. Neurourol Urodyn. 2001; 20: 669–682.

  • 14

    Schäfer W, Abrams P, Liao L, et al. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn. 2002; 21: 261–274.

  • 15

    Allert M, Jelasic F, Schneider H. Specific EMG findings in cases of neurogenic bladder and rectal disturbances. Paraplegia 1973; 10: 262–270.

  • 16

    Bacsu CD, Chan L, Tse V. Diagnosing detrusor sphincter dyssynergia in the neurological patient. BJU Int. 2012; 109(Suppl 3): 31–34.

  • 17

    Nosseir M, Hinkel A, Pannek J. Clinical usefulness of urodynamic assessment for maintenance of bladder function in patients with spinal cord injury. Neurourol Urodyn. 2007; 26: 228–233.

  • 18

    Marks BK, Goldman HB. Videourodynamics: indications and technique. Urol Clin North Am. 2014; 41: 383–391.

  • 19

    Franken J, Uvin P, De Ridder D, et al. TRP channels in lower urinary tract dysfunction. Br J Pharmacol. 2014; 171: 2537–2551.

  • 20

    Burkhard FC, Bosch JL, Cruz F, et al. European Association of Urology (EAU) Guidelines. Urinary Incontinence 2020. Available from: https://uroweb.org/guideline/urinary-incontinence [accessed: July 29, 2020].

  • 21

    Stöhrer M, Mürtz G, Kramer G, et al. Propiverine compared to oxybutynin in neurogenic detrusor overactivity. Results of a randomized, double-blind, multicenter clinical study. Eur Urol. 2007; 51: 235–242.

  • 22

    Chancellor MB, Erhard MJ, Hirsch IH, et al. Prospective evaluation of terazosin for the treatment of autonomic dysreflexia. J Urol. 1994; 151: 111–113.

  • 23

    Nitti VW, Rosenberg S, Mitcheson DH, et al. Urodynamics and safety of the β3-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013; 190: 1320–1327.

  • 24

    Szollar S, North J, Chung J. Antidiuretic hormone levels and polyuria in spinal cord injury. A preliminary report. Paraplegia 1995; 33: 94–97.

  • 25

    Bosma R, Wynia K, Havlíková E, et al. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand. 2005; 112: 1–5.

  • 26

    Everaerts W, Zhen X, Ghosh D, et al. Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis. Proc Natl Acad Sci. 2010; 107: 19084–19089.

  • 27

    Maggi CA, Santicioli P, Giuliani S, et al. The capsaicin-sensitive innervation of the rat urinary bladder: further studies on mechanisms regulating micturition threshold. J Urol. 1986; 136: 696–700.

  • 28

    Maggi CA, Barbanti G, Santicioli P, et al. Cystometric evidence that capsaicin-sensitive nerves modulate the afferent branch of micturition reflex in humans. J Urol. 1989; 142: 150–154.

  • 29

    Maggi CA. The dual function of capsaicin-sensitive sensory nerves in the bladder and urethra. Ciba Found Symp. 1990; 151: 77–83.; discussion 83–90.

  • 30

    Bley K. Effects of topical capsaicin on cutaneous innervation: implications for pain management. Open Pain J. 2012; 6(Suppl 1): 81–94.

  • 31

    Dasgupta P, Chandiramani V, Parkinson MC, et al. Treating the human bladder with capsaicin: is it safe? Eur Urol. 1998; 33: 28–31.

  • 32

    Oliveira R, Coelho A, Franquinho F, et al. Effects of early intravesical administration of resiniferatoxin to spinal cord-injured rats in neurogenic detrusor overactivity. Neurourol Urodyn. 2019; 38: 1540–1550.

  • 33

    Lazzeri M, Spinelli M, Beneforti P, et al. Intravesical resiniferatoxin for the treatment of detrusor hyperreflexia refractory to capsaicin in patients with chronic spinal cord diseases. Scand J Urol Nephrol. 1998; 32: 331–334.

  • 34

    Lazzeri M, Spinelli M, Zanollo A, et al. Intravesical vanilloids and neurogenic incontinence: ten years experience. Urol Int. 2004; 72: 145–149.

  • 35

    Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013; 189: 2186–2193.

  • 36

    Majoros A, Romics M. Diagnosis and treatment of the overactive bladder. [A hiperaktív hólyag kivizsgálása és kezelése.] LAM 2020; 30: 131–136. [Hungarian]

  • 37

    Lucas MG, Bosch RJ, Burkhard FC, et al. EAU guidelines on surgical treatment of urinary incontinence. Eur Urol. 2012; 62: 1118–1129.

  • 38

    Deng H, Liao L, Wu J, et al. Clinical efficacy of intravesical electrical stimulation on detrusor underactivity: 8 years of experience from a single center. Medicine (Baltimore) 2017; 96: e8020.

  • 39

    Banyó T. Current issues in neurourology. [A neurourológia aktuális kérdései.] Ideggyógy Szle. 2006; 59: 76–84. [Hungarian]